Vaxxinity, Inc.
vaxxinity.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 10-K, filed Mar 27, 2024. Its latest SEC filing is a 15-12G from May 9, 2024.
10-K for FY2023, filed Mar 27, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops synthetic peptide-based immunotherapy medicines for chronic diseases, with candidates aimed at treating patients and preventing illness in healthy people.
10-K for FY2023, filed Mar 27, 2024Today’s approach to treating patients suffering from chronic disease is focused on and increasingly dominated by drugs, particularly…View ↗
believe our synthetic peptide-basedView ↗
ActiveView ↗
Moreover, we believe that due to the unique features of our AIM Platform, these new medicines can enable an expansion from treating sick…View ↗
How Were They Changing?
-
Apr 19, 2024
Plans to delist its stock from Nasdaq
The company also planned to deregister its stock and suspend its SEC reporting obligations.
Sources
8-K, filed Apr 19, 2024
Stock Market LLC of its intention to voluntarily delist itsView ↗
Who Did They Compete With?
Competes with Pfizer, Merck, GlaxoSmithKline, Sanofi, Eisai, Lilly, Hoffman-LaRoche, AbbVie, Novartis, Amgen, Teva, Alder, Lundbeck, Allergan, and Biohaven
10-K for FY2023, filed Mar 27, 2024The global vaccine market is highly concentrated among a small number of multinational pharmaceutical companies: Pfizer,View ↗
Loading...
